Answers are grounded in this paper and cite their sources.
Transformed indolent non-Hodgkin lymphoma (tiNHL) has historically been associated with poor outcomes, particularly for patients with relapsed or refractory (R/R) disease. Although chimeric antigen receptor (CAR) T-cell therapy has improved prognosis, many patients lack access or experience relapse following treatment, highlighting the need for additional therapeutic strategies. CD3×CD20 bispecific antibodies (BsAbs) are active in R/R large B-cell lymphoma (LBCL), though data in tiNHL are limited. Here, we report the efficacy and safety of epcoritamab and glofitamab in patients with R/R tiNHL (N = 74) compared with those of patients with R/R de novo diffuse LBCL (DLBCL; N = 166) from 9 academic centers in the Collaborative US Bispecifics Consortium (CUBIC). With a median follow-up of 11.5 months, best overall response rate (ORR) and complete response rate (CRR) were comparable in tiNHL (50%/31%) vs de novo DLBCL (51%/34%). 12-month progression-free survival was 25% (95% confidence interval [CI], 15-39) for tiNHL vs 34% (95% CI, 27-43) for de novo DLBCL (HR, 1.15 [95% CI, 0.83-1.61]) and 12-month overall survival was 38% (95% CI, 26-55) for tiNHL vs 47% (95% CI, 39-56) for de novo DLBCL (HR, 1.08 [95% CI, 0.73-1.60]). No differences in toxicity were observed. Similar findings were found via a 1:1 propensity score matching statistical approach. In conclusion, our study revealed comparable efficacy and toxicity of BsAbs for patients with R/R tiNHL vs patients with R/R de novo DLBCL, supporting their use in this patient population.
No takes yet. Share an insight, caveat, or question.
Stephan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: